上肢深静脉血栓形成的抗凝治疗:系统评价与荟萃分析
本荟萃分析纳入11项前瞻性和9项回顾性研究共1473例上肢深静脉血栓形成患者,评估抗凝治疗的有效性与安全性。中位随访13个月,复发静脉血栓栓塞发生率为3%,大出血为3%,临床相关非大出血为4%,全因死亡率为9%;上述结局在有无癌症、有无留置导管及不同抗凝方案间无显著差异。
要点
- 上肢深静脉血栓形成患者抗凝治疗复发静脉血栓栓塞风险低(3%),但大出血风险不可忽视(3%)。
- 60%患者有留置导管,56.1%患者合并癌症。
- 有无癌症、有无留置导管及不同抗凝方案间上述结局无显著差异。
核心结论
- 在上肢深静脉血栓形成患者中,抗凝治疗与较低的复发静脉血栓栓塞风险相关,且大出血风险不可忽视。
研究设计与样本
- 系统检索MEDLINE和EMBASE,纳入11项前瞻性研究和9项回顾性研究,共1473例上肢深静脉血栓形成患者。
- 主要结局为复发静脉血栓栓塞和大出血,次要结局为临床相关非大出血和全因死亡率,采用随机效应荟萃分析计算汇总估计值及95%置信区间。
主要发现
- 中位随访13个月,复发静脉血栓栓塞发生率为3%(95%CI:2-4;21/1334例患者)。
- 大出血发生率为3%(95%CI:2%-5%;29/1235例患者),临床相关非大出血发生率为4%(95%CI:3-6;40/1075例患者)。
- 全因死亡率为9%(95%CI:5-15;108/1084例患者)。
- 上述结局在有无癌症、有无留置导管及接受不同抗凝治疗的患者间无显著差异。
关键数值与推荐
- 抗凝治疗方案包括直接口服抗凝药、低分子肝素后接维生素K拮抗剂、单用低分子肝素,分别占45.1%、35.0%和19.9%的患者。
- 60%的患者有留置导管,56.1%的患者合并癌症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on anticoagulant treatment for upper extremity deep vein thrombosis (UEDVT) are largely derived from studies on usual site venous thromboembolism (VTE). OBJECTIVES: The objective of this meta-analysis was to evaluate the efficacy and safety of anticoagulant therapy for UEDVT. PATIENTS/METHODS: A systematic search of MEDLINE and EMBASE was conducted for studies including patients with UEDVT. Primary outcomes were recurrent VTE and major bleeding. Secondary outcomes included clinically-relevant non-major bleeding and all-cause mortality. Summary estimates with 95% confidence intervals (CIs) were calculated by random-effect meta-analysis. RESULTS: A total of 1473 patients from 11 prospective and nine retrospective studies were included. Sixty percent of patients had an indwelling catheter and 56.1% had cancer. Anticoagulant treatment consisted of direct oral anticoagulants, low molecular weight heparin followed by vitamin K antagonists, and low molecular weight heparin alone in 45.1%, 35.0%, and 19.9% of patients, respectively. During a median follow-up of 13 months, recurrent VTE occurred in 3% of patients (95% CI: 2-4; 21/1334 patients), major bleeding in 3% (95% CI: 2%-5%; 29/1235 patients), clinically-relevant non-major bleeding in 4% (95% CI: 3-6; 40/1075 patients), and all-cause mortality in 9% (95% CI: 5-15; 108/1084 patients). Rates of these outcomes were not significantly different between patients with or without cancer, patients with or without an indwelling catheter, and among those receiving different anticoagulant treatments. CONCLUSIONS: In patients with UEDVT, anticoagulant treatment is associated with a low risk of recurrent VTE and a nonnegligible risk of major bleeding.
引用
- Valeriani E, Di Nisio M, Porceddu E, et al. Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis. J Thromb Haemost. 2021. PMID: 34846783. doi:10.1111/jth.15614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。